We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

She founded ARK Investment Management around ... beating its benchmark by 150 percentage points (see more details here). CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO ... who’s the sort of the founder of all the CAR-Ts, came up with their own analysis and ...

to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

The JV will be led by Dr Axel Bouchon, head of the BLSC, on an interim basis as CEO, while Dr Rodger Novak, CEO and co-founder of CRISPR Therapeutics, will serve as the interim chairman of the ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...